Individual patient characteristics and outcome
| Patients . | Fusion gene . | Sex . | Age, y . | WBC, ×109/L . | IKZF1 . | Front-line trial . | Prednisone response, day 8 . | MRD response to induction* . | Time to TKI initiation, d† . | TKI (dose, mg daily) . | Treatment combined with TKI . | First MRD post-TKI (d‡) . | Best MRD in CCR (d‡) . | HSCT§ . | Survival (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In first line | |||||||||||||||
| 1 | EBF1-PDGFRB | M | 16 | 167 | del | FRALLE-2000B | Poor | 2 × 10−1 | 55 | Imatinib (400) | Chemo | 5 × 10−3 (21) | Neg (50) | Y | Alive in CR1 (62) |
| 2 | EBF1-PDGFRB | M | 11 | 154 | wt | FRALLE-2000B | Poor | 2 × 10−2 | 44 | Imatinib (300) | Chemo | Neg (44) | Neg (44) | N | Alive in CR1 (50) |
| 3 | EBF1-PDGFRB | M | 5 | 23 | wt | FRALLE-2000A | Poor | No CR (35%) | 39 | Imatinib (NA) | Chemo | >10−2 (18) | Neg (45) | N | Alive in CR1 (50) |
| 4 | EBF1-PDGFRB | M | 15 | 31 | wt | EORTC 58081-AR1 | Good | 5 × 10−3 | 137 | Imatinib (500) | Chemo | Neg (109) | Neg (109) | N | Alive in CR1 (43) |
| 5 | EBF1-PDGFRB | M | 17 | 6 | wt | CAALL-01 | Good | No CR (60%) | 38 | Imatinib (550) | Chemo | 4 × 10−4 (48) | +<10−4 (62) | Y | Alive in CR1 (23) |
| 6 | EBF1-PDGFRB | M | 36 | 45 | wt | GRAALL-2014 | Poor | 8 × 10−3 | 44 | Imatinib (400) | Chemo | +<10−4 (35) | Neg (78) | Y | Alive in CR1 (23) |
| 7 | NUMA1-PDGFRB | M | 61 | 4 | wt | VCR-DEX-Ritux | Good | 1 × 10−3 | 39 | Dasatinib (100) | Chemo | Neg (67) | Neg (67) | N | Alive in CR2 (36) |
| 8 | ETV6-PDGFRB | F | 72 | 16 | Wt | EWALL-BB | Good | 1 × 10−2 | 38 | Imatinib (600) | Chemo | 2 × 10−3 (91) | 1 × 10−4 (252) | N | Alive in CR1 (29) |
| 330 | Dasatinib (NA) | Chemo | Neg (120) | Neg (120) | |||||||||||
| 9 | ATF7IP-PDGFRB | F | 54 | 13 | wt | GRAALL-2014 | Poor | 1 × 10−4 | 15 | Dasatinib (100) | Chemo | 1 × 10−4 (15) | Neg (77) | N | Death in CR2 (16) |
| 10 | NUP214-ABL1 | M | 16 | 30 | del | EORTC 58081- | Poor | No CR (34%) | 81 | Imatinib (550) | Chemo | No CR (23) | No CR (23) | Y | Alive in CR1 (45) |
| AR1 | 104 | Dasatinib (140) | Chemo | >10−2 (71) | 1 × 10−2 (114) | ||||||||||
| 11 | NUP214-ABL1 | M | 17 | 114 | del | FRALLE-2000B | Good | 2 × 10−1 | 89 | Imatinib (500) | Chemo, Blin | 8 × 10−2 (26) | Neg (54) | Y | Alive in CR1 (43) |
| 98 | Dasatinib (140) | (114) | |||||||||||||
| 12 | NUP214-ABL1 | F | 24 | 11 | del | FRALLE-2000B | Poor | 2 × 10−3 | 49 | Imatinib (400) | Chemo | Neg (65) | Neg (65) | Y | Alive in REL1 (29) |
| 13 | NUP214-ABL1 | F | 31 | 70 | del | GRAALL-2014 | Poor | No CR (12%) | 61 | Dasatinib (140) | Chemo | NA | NA | N | Death in REL1 (9) |
| 14 | NUP214-ABL1 | M | 18 | 18 | wt | GRAALL-2014 | NA | No CR (9%) | 70 | Dasatinib (100) | Chemo | 8 × 10−2 (14) | Neg (125) | Y | Alive in CR1 (11) |
| 15 | RCSD1-ABL1 | F | 26 | 29 | wt | GRAALL-2014 | Good | 6 × 10−3 | 69 | Dasatinib (NA) | Chemo | 2 × 10−3 (85) | 5 × 10−4 (125) | Y | Alive in CR1 (27) |
| 16 | LSM14A-ABL1 | M | 36 | 390 | del | VCR-DEX-Ritux | Poor | No CR (7%) | 49 | Dasatinib (NA) | Chemo | No CR (15) | NA | N | Death, REF (2) |
| 17 | ZC3HAV1-ABL2 | M | 27 | 30 | del | GRAALL-2014 | NA | 9 × 10−4 | 58 | Imatinib (600) | Chemo | 2 × 10−4 (44) | Neg (175) | Y | Alive in CR1 (8) |
| 18 | MEF2D-CSF1R | M | 34 | 89 | wt | GRAALL-2014 | Poor | 1 × 10−2 | 20 | Imatinib (NA) | Chemo | 1 × 10−4 (96) | Neg (147) | N | Death in REL1 (13) |
| 19 | ZMYM2-FGFR1 | M | 23 | 53 | wt | GRAALL-2005 | Poor | No CR (55%) | 67 | Ponatinib (30) | Chemo | 2 × 10−2 (39) | 2 × 10−3 (175) | N | Death in REL3 (37) |
| In relapse | |||||||||||||||
| 20 | ETV6-ABL1 | M | 12 | NA | del | FRALLE-2000B | Good | +<10−4 | REL1 | Dasatinib (100) | Chemo | Neg (25) | Neg (25) | Y | Alive in CR2 (124) |
| 21 | ETV6-ABL1 | M | 14 | 570 | del | FRALLE-2000B | Poor | 2 × 10−2 | REL1 | Imatinib (NA) | Chemo | 1 × 10−3 (21) | +<10−4 (49) | Y | Alive in CR2 (59) |
| 22 | RANBP2-ABL1 | F | 20 | 6 | del | GRAALL-2005R | Good | <10−4 | REL2, REF | Dasatinib (140) | Chemo | 7 × 10−2 (60) | 8 × 10−3 (87) | N | Death in REL3 (29) |
| 23 | ETV6-ABL1 | F | 61 | 10 | wt | EWALL-BB | Poor | No CR (75%) | REL1 | Imatinib (400) | Chemo | 5 × 10−3 (34) | Neg (245) | N | Death in REL2 (28) |
| 24 | NUP214-ABL1 | F | 15 | 237 | del | EORTC 58081-VHR | Poor | >10−2 | REL3 | Dasatinib (140) | Chemo, DLI | 3 × 10−2 (27) | NA | N | Death in REL5 (60) |
| Patients . | Fusion gene . | Sex . | Age, y . | WBC, ×109/L . | IKZF1 . | Front-line trial . | Prednisone response, day 8 . | MRD response to induction* . | Time to TKI initiation, d† . | TKI (dose, mg daily) . | Treatment combined with TKI . | First MRD post-TKI (d‡) . | Best MRD in CCR (d‡) . | HSCT§ . | Survival (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In first line | |||||||||||||||
| 1 | EBF1-PDGFRB | M | 16 | 167 | del | FRALLE-2000B | Poor | 2 × 10−1 | 55 | Imatinib (400) | Chemo | 5 × 10−3 (21) | Neg (50) | Y | Alive in CR1 (62) |
| 2 | EBF1-PDGFRB | M | 11 | 154 | wt | FRALLE-2000B | Poor | 2 × 10−2 | 44 | Imatinib (300) | Chemo | Neg (44) | Neg (44) | N | Alive in CR1 (50) |
| 3 | EBF1-PDGFRB | M | 5 | 23 | wt | FRALLE-2000A | Poor | No CR (35%) | 39 | Imatinib (NA) | Chemo | >10−2 (18) | Neg (45) | N | Alive in CR1 (50) |
| 4 | EBF1-PDGFRB | M | 15 | 31 | wt | EORTC 58081-AR1 | Good | 5 × 10−3 | 137 | Imatinib (500) | Chemo | Neg (109) | Neg (109) | N | Alive in CR1 (43) |
| 5 | EBF1-PDGFRB | M | 17 | 6 | wt | CAALL-01 | Good | No CR (60%) | 38 | Imatinib (550) | Chemo | 4 × 10−4 (48) | +<10−4 (62) | Y | Alive in CR1 (23) |
| 6 | EBF1-PDGFRB | M | 36 | 45 | wt | GRAALL-2014 | Poor | 8 × 10−3 | 44 | Imatinib (400) | Chemo | +<10−4 (35) | Neg (78) | Y | Alive in CR1 (23) |
| 7 | NUMA1-PDGFRB | M | 61 | 4 | wt | VCR-DEX-Ritux | Good | 1 × 10−3 | 39 | Dasatinib (100) | Chemo | Neg (67) | Neg (67) | N | Alive in CR2 (36) |
| 8 | ETV6-PDGFRB | F | 72 | 16 | Wt | EWALL-BB | Good | 1 × 10−2 | 38 | Imatinib (600) | Chemo | 2 × 10−3 (91) | 1 × 10−4 (252) | N | Alive in CR1 (29) |
| 330 | Dasatinib (NA) | Chemo | Neg (120) | Neg (120) | |||||||||||
| 9 | ATF7IP-PDGFRB | F | 54 | 13 | wt | GRAALL-2014 | Poor | 1 × 10−4 | 15 | Dasatinib (100) | Chemo | 1 × 10−4 (15) | Neg (77) | N | Death in CR2 (16) |
| 10 | NUP214-ABL1 | M | 16 | 30 | del | EORTC 58081- | Poor | No CR (34%) | 81 | Imatinib (550) | Chemo | No CR (23) | No CR (23) | Y | Alive in CR1 (45) |
| AR1 | 104 | Dasatinib (140) | Chemo | >10−2 (71) | 1 × 10−2 (114) | ||||||||||
| 11 | NUP214-ABL1 | M | 17 | 114 | del | FRALLE-2000B | Good | 2 × 10−1 | 89 | Imatinib (500) | Chemo, Blin | 8 × 10−2 (26) | Neg (54) | Y | Alive in CR1 (43) |
| 98 | Dasatinib (140) | (114) | |||||||||||||
| 12 | NUP214-ABL1 | F | 24 | 11 | del | FRALLE-2000B | Poor | 2 × 10−3 | 49 | Imatinib (400) | Chemo | Neg (65) | Neg (65) | Y | Alive in REL1 (29) |
| 13 | NUP214-ABL1 | F | 31 | 70 | del | GRAALL-2014 | Poor | No CR (12%) | 61 | Dasatinib (140) | Chemo | NA | NA | N | Death in REL1 (9) |
| 14 | NUP214-ABL1 | M | 18 | 18 | wt | GRAALL-2014 | NA | No CR (9%) | 70 | Dasatinib (100) | Chemo | 8 × 10−2 (14) | Neg (125) | Y | Alive in CR1 (11) |
| 15 | RCSD1-ABL1 | F | 26 | 29 | wt | GRAALL-2014 | Good | 6 × 10−3 | 69 | Dasatinib (NA) | Chemo | 2 × 10−3 (85) | 5 × 10−4 (125) | Y | Alive in CR1 (27) |
| 16 | LSM14A-ABL1 | M | 36 | 390 | del | VCR-DEX-Ritux | Poor | No CR (7%) | 49 | Dasatinib (NA) | Chemo | No CR (15) | NA | N | Death, REF (2) |
| 17 | ZC3HAV1-ABL2 | M | 27 | 30 | del | GRAALL-2014 | NA | 9 × 10−4 | 58 | Imatinib (600) | Chemo | 2 × 10−4 (44) | Neg (175) | Y | Alive in CR1 (8) |
| 18 | MEF2D-CSF1R | M | 34 | 89 | wt | GRAALL-2014 | Poor | 1 × 10−2 | 20 | Imatinib (NA) | Chemo | 1 × 10−4 (96) | Neg (147) | N | Death in REL1 (13) |
| 19 | ZMYM2-FGFR1 | M | 23 | 53 | wt | GRAALL-2005 | Poor | No CR (55%) | 67 | Ponatinib (30) | Chemo | 2 × 10−2 (39) | 2 × 10−3 (175) | N | Death in REL3 (37) |
| In relapse | |||||||||||||||
| 20 | ETV6-ABL1 | M | 12 | NA | del | FRALLE-2000B | Good | +<10−4 | REL1 | Dasatinib (100) | Chemo | Neg (25) | Neg (25) | Y | Alive in CR2 (124) |
| 21 | ETV6-ABL1 | M | 14 | 570 | del | FRALLE-2000B | Poor | 2 × 10−2 | REL1 | Imatinib (NA) | Chemo | 1 × 10−3 (21) | +<10−4 (49) | Y | Alive in CR2 (59) |
| 22 | RANBP2-ABL1 | F | 20 | 6 | del | GRAALL-2005R | Good | <10−4 | REL2, REF | Dasatinib (140) | Chemo | 7 × 10−2 (60) | 8 × 10−3 (87) | N | Death in REL3 (29) |
| 23 | ETV6-ABL1 | F | 61 | 10 | wt | EWALL-BB | Poor | No CR (75%) | REL1 | Imatinib (400) | Chemo | 5 × 10−3 (34) | Neg (245) | N | Death in REL2 (28) |
| 24 | NUP214-ABL1 | F | 15 | 237 | del | EORTC 58081-VHR | Poor | >10−2 | REL3 | Dasatinib (140) | Chemo, DLI | 3 × 10−2 (27) | NA | N | Death in REL5 (60) |
Blin, blinatumomab; CAALL, French Protocol for the Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents; CCR, continuous complete remission; Chemo, polychemotherapy; CR, complete remission; CR1, complete remission 1; CR2, complete remission 2; del, intragenic deletion; DLI, donor lymphocyte infusion; EORTC, European Organisation for Research and Treatment of Cancer; EWALL, European Working Group on Adult ALL; F, female; FRALLE, French Acute Lymphoblastic Leukaemia Study Group; GRAALL, French-Swiss-Belgian Group for Research on Adult Acute Lymphoblastic Leukemia; M, male; NA, not available; Neg, negative; REF, refractory; REL1, relapse 1; REL2, relapse 2; REL3, relapse 3; REL5, relapse 5; VCR-DEX-Ritux, vincristine-dexamethasone-rituximab; VHR, very high risk; WBC, white blood cell count; wt, wild type.
MRD in case of morphological CR, or the percentage of blasts in refractory patients.
From diagnosis, or disease status for patients in relapse.
From TKI initiation.
HSCT in CCR after TKI initiation.